Tenax Therapeutics, Inc. (TENX) Key Metrics

NASDAQ: TENXValuation, returns, debt and efficiency ratios over 10 years.

TENX valuation today

Trailing 12 months · as of October 18, 2026
Market cap
$50.9M
Enterprise value
−$46.3M
P/E (TTM)
—
Forward P/E
0.3
PEG ratio
1.44
Price / sales
414.7
Price / book
0.6
EV / EBITDA
—
Dividend yield
—
Beta
0.92

TENX key metrics, 2016–2025

Fiscal year ended December 31, 2025 · U.S. dollars

TENX valuation Price multiples at each fiscal year-end price.

Price / book+379.3%
4.9
2025 · hover or tap a bar for each year
2024: 1.02025: 4.9 (+379.3%)
20162025
Free cash flow yield+8.2 pts
−7.5%
2025 · hover or tap a bar for each year
2024: −15.7%2025: −7.5% (+8.2 pts)
20162025

TENX valuation history

Fiscal year-endToday10-year median

TENX returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

TENX debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

TENX cash returned to shareholders

DividendsBuybacksFree cash flow

TENX price vs earnings per share

Share price at year-endEPS (right axis)

TENX key metrics

2016–2025
Tenax Therapeutics, Inc. key metrics by fiscal year
2025202420232022202120202019201820172016
Valuation
Market capitalization$478.1M$94.5M————————
Enterprise value$380.5M−$319,146————————
Price / book4.91.0————————
Earnings yield−11.0%−18.6%————————
Free cash flow yield−7.5%−15.7%————————
Share price at fiscal year-end$12.19$6.19$21.97$178.24$1,664.00$2,976.00$2,256.00$1,936.00$15,680.00$62,400.00
Per share
Revenue per share$0.00$0.00————————
Earnings per share−$1.34−$1.15————————
Operating cash flow per share−$0.91−$0.97————————
Free cash flow per share−$0.91−$0.97————————
Cash per share$2.49$6.21————————
Book value per share$2.48$6.02————————
Tangible book value per share$2.48$6.02————————
Capex per share$0.00$0.00————————
Shares outstanding39.2M15.3M————————
Change in shares outstanding+156.8%—————————
Returns & profitability
Return on equity (ROE)−55.6%−35.2%−160.8%−385.1%−732.2%−234.6%−108.0%−66.0%−67.9%−113.3%
Return on invested capital (ROIC)————————−290.0%−188.2%
Return on assets (ROA)−52.4%−32.5%−102.2%−235.1%−505.0%−148.9%−85.2%−58.7%−53.2%−91.2%
Return on tangible assets−50.5%−18.2%−66.0%−324.5%−541.9%−143.4%−131.9%−51.1%−89.4%—
Financial health
Total debt——$500,903$807,891$290,781$305,036$171,732—$0$0
Cash & short-term investments$97.6M$94.9M$9.8M$2.1M$5.6M$6.7M$5.4M$12.9M$7.7M$13.3M
Net debt−$97.6M−$94.9M−$9.3M−$1.3M−$5.3M−$6.4M−$5.2M−$12.9M−$7.7M−$13.3M
Debt / equity——0.060.540.070.070.05—0.000.00
Debt / assets——0.040.240.050.040.03—0.000.00
Current ratio14.5620.603.261.743.643.212.448.517.992.20
Quick ratio14.5620.603.261.743.643.212.448.517.992.20
Interest coverage—-847.6-343.6——————-1.6
Working capital$97.1M$92.0M$8.1M$1.4M$4.1M$4.7M$3.6M$11.8M$7.1M$7.4M
Invested capital−$494,000−$2.9M−$1.2M$176,950−$1.0M−$1.8M−$1.5M−$1.1M$1.2M$3.9M
Tangible asset value$97.1M$92.0M$8.1M$1.5M$4.2M$4.6M$3.8M$11.8M$8.9M−$4.9M
Net current asset value$97.1M$92.0M$8.1M$1.3M$3.9M$4.6M$3.6M$11.8M$7.1M$7.4M
Graham net-net per share$2.31$5.90————————
Capital allocation
Dividends paid———————$7.3M$0$0
Share buybacks (net)—————$0$0$0$0$0
Capex / depreciation—0.000.360.020.050.030.030.840.330.15
Efficiency
Days payables outstanding——60,790.92,106.42,708.63,847.14,101.327,565.817,946.716,371.1
Receivables turnover———————0.000.000.00
Payables turnover——0.010.170.130.090.090.010.020.02
Asset turnover0.000.000.000.000.000.000.000.000.000.00
Average receivables———————$25,086$61,385$61,024
Average payables$4.6M$2.6M$1.3M$654,032$808,747$1.2M$1.2M$680,838$669,730$850,041
Average inventory————————$0$82,167
Intangibles / total assets0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%94.3%

Computed from TENX's annual financial statements (latest annual report filed March 10, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

TENX valuation and financial ratios

Tenax Therapeutics earned a return on equity of −55.6% in fiscal 2025.

See the TENX income statement, the TENX chart for price history, or the TENX stock overview for the latest quote and news.

TENX key metrics FAQ

What is Tenax Therapeutics's return on equity?

Tenax Therapeutics's return on equity (ROE) was −55.6% in fiscal 2025: net income of -$52.6 million on average shareholders' equity of $94.5 million.

What is Tenax Therapeutics's free cash flow yield?

Tenax Therapeutics generated -$35.8 million of free cash flow in fiscal 2025, a free cash flow yield of −7.5% on its market value at year-end ($478.1 million).

What is Tenax Therapeutics's current ratio?

Tenax Therapeutics's current ratio was 14.56 at the end of fiscal 2025: current assets were 14.56 times current liabilities.

Biotechnology key metrics